• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.

作者信息

Klausen Tobias W, Gregersen Henrik, Abildgaard Niels, Andersen Niels Frost, Frølund Ulf Christian, Gimsing Peter, Helleberg Carsten, Vangsted Annette J

机构信息

Department of Hematology, Herlev Hospital, Herlev, Denmark.

Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.

出版信息

Leukemia. 2019 Feb;33(2):546-549. doi: 10.1038/s41375-018-0272-0. Epub 2018 Sep 28.

DOI:10.1038/s41375-018-0272-0
PMID:30267010
Abstract
摘要

相似文献

1
The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.大多数新诊断的骨髓瘤患者不符合III期临床试验的纳入标准。
Leukemia. 2019 Feb;33(2):546-549. doi: 10.1038/s41375-018-0272-0. Epub 2018 Sep 28.
2
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.新诊断多发性骨髓瘤患者随机对照试验的常见纳入标准分析及结果推断
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2. doi: 10.1016/j.clml.2017.06.013. Epub 2017 Jun 17.
3
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.自体移植治疗新诊断多发性骨髓瘤在新型诱导药物时代：系统评价和荟萃分析。
JAMA Oncol. 2018 Mar 1;4(3):343-350. doi: 10.1001/jamaoncol.2017.4600.
4
Therapy for relapsed multiple myeloma.复发多发性骨髓瘤的治疗。
Panminerva Med. 2018 Dec;60(4):174-184. doi: 10.23736/S0031-0808.18.03542-5. Epub 2018 Oct 5.
5
Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma.在一项针对多发性骨髓瘤的多阶段随机临床试验中，采用逆概率加权法估计单个阶段的因果效应。
BMC Med Res Methodol. 2016 Nov 9;16(1):150. doi: 10.1186/s12874-016-0253-9.
6
Age demographics of subjects enrolled in interventional phase 3 multiple myeloma clinical trials.参与3期多发性骨髓瘤介入性临床试验受试者的年龄分布情况。
J Oncol Pharm Pract. 2020 Sep;26(6):1475-1481. doi: 10.1177/1078155220934162. Epub 2020 Jul 1.
7
Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma.双膦酸盐类药物不会延迟新诊断骨髓瘤患者自体造血干细胞移植后的植入。
Bone Marrow Transplant. 2015 Jan;50(1):157. doi: 10.1038/bmt.2014.225. Epub 2014 Oct 13.
8
Hematology: Setting the standard for newly diagnosed multiple myeloma.
Nat Rev Clin Oncol. 2011 May;8(5):255-6. doi: 10.1038/nrclinonc.2011.43. Epub 2011 Mar 22.
9
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect MM Registry.新诊断多发性骨髓瘤老年患者的治疗模式与结局：来自Connect MM注册研究的结果
Blood Cancer J. 2021 Jul 23;11(7):134. doi: 10.1038/s41408-021-00524-1.
10
Clinical trials referral resource. Multiple myeloma and Waldenström's macroglobulinemia phase III trials.
Oncology (Williston Park). 1994 Jul;8(7):45, 48-50.

引用本文的文献

1
Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer.多重用药可独立预测淋巴癌患者的生存率、住院率及感染情况。
Hemasphere. 2025 Jul 16;9(7):e70172. doi: 10.1002/hem3.70172. eCollection 2025 Jul.
2
One for the ages: impact of age on international prognostic indices in lymphoid cancer.献给岁月的研究：年龄对淋巴癌国际预后指数的影响
Blood Adv. 2025 Aug 26;9(16):4260-4264. doi: 10.1182/bloodadvances.2025016534.
3
A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma.
一种用于新诊断多发性骨髓瘤患者的真实世界国际分期系统（RW-ISS）。
Blood Cancer J. 2025 Apr 7;15(1):59. doi: 10.1038/s41408-025-01268-y.
4
Comparing the clinical trial efficacy real-world effectiveness of treatments for multiple myeloma: a population-based study.比较多发性骨髓瘤治疗的临床试验疗效与真实世界有效性：一项基于人群的研究。
Haematologica. 2025 Jan 1;110(1):228-233. doi: 10.3324/haematol.2024.285768.
5
Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real-world study.来那度胺维持治疗在多发性骨髓瘤中的全国性实施：一项回顾性真实世界研究。
EJHaem. 2024 Mar 27;5(2):316-324. doi: 10.1002/jha2.881. eCollection 2024 Apr.
6
Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution.根据临床试验入组情况分析新诊断的不适合移植的多发性骨髓瘤患者的预后：单中心经验
Cancers (Basel). 2023 Nov 2;15(21):5261. doi: 10.3390/cancers15215261.
7
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.初诊多发性骨髓瘤患者真实世界未选择人群的临床结局和血清 B 细胞成熟抗原水平。
Target Oncol. 2023 Sep;18(5):735-747. doi: 10.1007/s11523-023-00990-6. Epub 2023 Sep 8.
8
Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden.多发性骨髓瘤患者的生存改善——丹麦和瑞典≥75 岁 4647 例患者的全国登记研究。
Haematologica. 2023 Jun 1;108(6):1640-1651. doi: 10.3324/haematol.2021.280424.
9
Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016.2005-2016 年芬兰诊断的多发性骨髓瘤患者的合并症特征。
Ann Hematol. 2022 Nov;101(11):2485-2495. doi: 10.1007/s00277-022-04959-9. Epub 2022 Sep 13.
10
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.540 例新诊断骨髓瘤患者自体干细胞移植前诱导治疗改变对其影响的回顾性真实世界研究。
J Cancer Res Clin Oncol. 2023 Jul;149(7):3739-3752. doi: 10.1007/s00432-022-04184-x. Epub 2022 Aug 20.